NCT00509431View on ClinicalTrials.gov

Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

September 30, 2012

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

Erlotinib + Sirolimus

In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00509431 - Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter